

Ref. No: 1547  
Date: 12/02/25  
Subject: Oncology RCC

## REQUEST

I have a freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

**Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for Renal Cell Carcinoma? If not, which other trust do you refer Renal Cell Carcinoma patients to for SACT treatments?**

**Q2. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :**

- Avelumab + Axitinib
- Axinitib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

## RESPONSE

1. Renal Cell Carcinoma would be an oncology regimen which would be managed out of Clatterbridge Centre for Oncology

<https://www.wuth.nhs.uk/our-locations/clatterbridge-hospital/>

2. Patients diagnosed with Renal Cell Carcinoma who received palliative care only between 01.10.24 and 31.12.24.

St Helen's & Knowsley	Southport & Ormskirk	MWL
<5	<5	<5